Golden
Stelvio Therapeutics

Stelvio Therapeutics

Stelvio Therapeutics is a biotechnology company developing therapeutics for cancer.

Stelvio Therapeutics is a privately held, biotechnology company based in San Diego, California that was founded in 2017 by Attila Hajdu. The company focuses on developing a pipeline of alternative treatments for malignant glioblastoma multiforme (GBM), the most common and lethal brain tumor. 



Stelvio's approach to treating cancer involves identifying compounds that drive the differentiation of cancer stem cells into benign cell types. It then induces the differentiation of tumor propagating cells into non-tumorigenic cells.

Partnerships

Johnson & Johnson Innovation

In March 2018, Stelvio Therapeutics joined Johnson & Johnson Innovation JLABS. Around the same time, i2020 Accelerator announced that Stelvio had joined its early drug discovery ecosystem to advance its proprietary epigenetic platform for glioblastoma therapies. i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year framework. It 

Funding

Seed

On May 5, 2017 Stevlio Therapeutics completed their seed funding round with and undisclosed amount of funding from SOSV and IndieBio. 

Timeline

People

Name
Role
Related Golden topics

Alexey V. Terskikh

Co-Founder



Attila Hajdu

Founder & CEO



Further reading

Title
Author
Link
Type

i2020 to Accelerate Stelvio Therapeutics First-in-Class Epigenetic Platform for Glioblastoma

Stelvio Therapeutics

Web

Stelvio Therapeutics joins JLABS San Diego

Stelvio Therapeutics

Web

Tune in to IndieBio Accelerator's Demo Day today

Neesha A. Tambe

Web

Documentaries, videos and podcasts

Title
Date
Link

IndieBio SF Live Stream Demo Day 5 (9/14/2017)

September 14, 2017

Companies

Company
CEO
Location
Products/Services









References